-DOCSTART- -X- O
Fc -X- _ B-Patient
receptors -X- _ I-Patient
( -X- _ I-Patient
FcRs -X- _ I-Patient
) -X- _ I-Patient
belong -X- _ O
to -X- _ O
the -X- _ O
ITAM-associated -X- _ O
receptor -X- _ O
family. -X- _ O
FcRs -X- _ B-Outcome
control -X- _ I-Outcome
the -X- _ I-Outcome
humoral -X- _ I-Outcome
and -X- _ I-Outcome
innate -X- _ I-Outcome
immunity -X- _ I-Outcome
which -X- _ O
are -X- _ O
essential -X- _ O
for -X- _ O
appropriate -X- _ O
responses -X- _ O
to -X- _ O
infections -X- _ O
and -X- _ O
prevention -X- _ O
of -X- _ O
chronic -X- _ O
inflammation -X- _ O
or -X- _ O
auto-immune -X- _ O
diseases. -X- _ O
Following -X- _ O
their -X- _ O
crosslinking -X- _ O
by -X- _ O
immune -X- _ O
complexes -X- _ O
, -X- _ O
FcRs -X- _ O
play -X- _ O
various -X- _ O
roles -X- _ O
such -X- _ O
as -X- _ O
modulation -X- _ B-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
immune -X- _ I-Outcome
response -X- _ I-Outcome
by -X- _ I-Outcome
released -X- _ I-Outcome
cytokines -X- _ I-Outcome
or -X- _ I-Outcome
of -X- _ I-Outcome
phagocytosis. -X- _ I-Outcome
Here -X- _ O
, -X- _ O
we -X- _ O
review -X- _ O
FcR -X- _ O
involvement -X- _ O
in -X- _ O
pathologies -X- _ O
leading -X- _ O
notably -X- _ O
to -X- _ O
altered -X- _ O
intracellular -X- _ O
signaling -X- _ O
with -X- _ O
functionally -X- _ O
relevant -X- _ O
consequences -X- _ O
to -X- _ O
the -X- _ O
host -X- _ O
, -X- _ O
and -X- _ O
targeting -X- _ O
of -X- _ O
Fc -X- _ O
receptors -X- _ O
as -X- _ O
therapeutic -X- _ O
approaches. -X- _ O
Special -X- _ O
emphasis -X- _ O
will -X- _ O
be -X- _ O
given -X- _ O
to -X- _ O
some -X- _ O
FcRs -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
the -X- _ O
FcαRI -X- _ B-Patient
, -X- _ I-Patient
the -X- _ I-Patient
FcγRIIA -X- _ I-Patient
and -X- _ I-Patient
the -X- _ I-Patient
FcγRIIIA -X- _ I-Patient
, -X- _ O
which -X- _ O
behave -X- _ O
like -X- _ O
the -X- _ O
ancient -X- _ O
god -X- _ O
Janus -X- _ O
depending -X- _ O
on -X- _ O
the -X- _ O
ITAM -X- _ O
motif -X- _ O
to -X- _ O
inhibit -X- _ O
or -X- _ O
activate -X- _ O
immune -X- _ O
responses -X- _ O
depending -X- _ O
on -X- _ O
their -X- _ O
targeting -X- _ O
by -X- _ O
monomeric -X- _ O
/ -X- _ O
dimeric -X- _ O
immunoglobulins -X- _ O
or -X- _ O
by -X- _ O
immune -X- _ O
complexes. -X- _ O
This -X- _ O
ITAM -X- _ O
duality -X- _ O
has -X- _ O
been -X- _ O
recently -X- _ O
defined -X- _ O
as -X- _ O
inhibitory -X- _ O
or -X- _ O
activating -X- _ O
ITAM -X- _ O
( -X- _ O
ITAMi -X- _ O
or -X- _ O
ITAMa -X- _ O
) -X- _ O
which -X- _ O
are -X- _ O
controlled -X- _ O
by -X- _ O
Src -X- _ O
family -X- _ O
kinases. -X- _ O
Involvement -X- _ O
of -X- _ O
various -X- _ O
ITAM-bearing -X- _ O
FcRs -X- _ O
observed -X- _ O
during -X- _ O
infectious -X- _ O
or -X- _ O
autoimmune -X- _ O
diseases -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
allelic -X- _ O
variants -X- _ O
, -X- _ O
changes -X- _ O
in -X- _ O
ligand -X- _ O
binding -X- _ O
ability -X- _ O
responsible -X- _ O
for -X- _ O
host -X- _ O
defense -X- _ O
perturbation. -X- _ O
During -X- _ O
auto-immune -X- _ O
diseases -X- _ O
such -X- _ O
as -X- _ O
rheumatoid -X- _ O
arthritis -X- _ O
, -X- _ O
lupus -X- _ O
or -X- _ O
immune -X- _ O
thrombocytopenia -X- _ O
, -X- _ O
the -X- _ B-Outcome
autoantibodies -X- _ I-Outcome
and -X- _ I-Outcome
immune -X- _ I-Outcome
complexes -X- _ I-Outcome
lead -X- _ I-Outcome
to -X- _ I-Outcome
inflammation -X- _ I-Outcome
through -X- _ I-Outcome
FcR -X- _ I-Outcome
aggregation. -X- _ I-Outcome
We -X- _ O
will -X- _ O
discuss -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
FcRs -X- _ O
in -X- _ O
autoimmune -X- _ O
diseases -X- _ O
, -X- _ O
and -X- _ O
focus -X- _ O
on -X- _ O
novel -X- _ O
approaches -X- _ O
to -X- _ O
target -X- _ O
FcRs -X- _ O
for -X- _ O
resolution -X- _ O
of -X- _ O
antibody-mediated -X- _ O
autoimmunity. -X- _ O
We -X- _ O
will -X- _ O
finally -X- _ O
also -X- _ O
discuss -X- _ O
the -X- _ O
down-regulation -X- _ O
of -X- _ O
FcR -X- _ O
functionality -X- _ O
as -X- _ O
a -X- _ O
therapeutic -X- _ O
approach -X- _ O
for -X- _ O
autoimmune -X- _ O
diseases -X- _ O
. -X- _ O

